A Phase 3 interventional study of Avatrombopag 60 mg in Thrombocytopenia, sponsored by Sobi, Inc.. Terminated at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.
Sponsored by Sobi, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.
Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 21st largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 7th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 6 · Phase 4 4
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 50 across the 23 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sobi, Inc., one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
Sobi, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Swedish Orphan Biovitrum has 5 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing avatrombopag in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.
Subjects will receive oral avatrombopag once daily for 5 days beginning on Day 1, followed by a wait period prior to the procedure, which will occur on Day 10 to 13. The Follow-up Period will include 2 visits; 7 days post-procedure and 30 days after last dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A mean baseline count between:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label: oral avatrombopag
Drug: Avatrombopag 60 mg
Oral avatrombopag administered once daily for 5 days prior to procedure.
Evaluate Efficacy of Avatrombopag in Increasing Platelet Counts in Subjects With Thrombocytopenia Scheduled for Operations
Proportion of subjects that achieve a platelet count \>100 x 10\^9 platelets/L on procedure day
Time frame: Baseline to 10-13 days
Evaluate Safety of Avatrombopag: Incidence of Treatment Emergent Adverse Events
Incidence of treatment emergent adverse events
Time frame: Up to 35 days
| Milestone | Avatrombopag 60 mg |
|---|---|
| Started | 4 |
| Completed | 4 |
| Not completed | 0 |
Proportion of subjects that achieve a platelet count \>100 x 10\^9 platelets/L on procedure day
| proportion of total participants | Avatrombopag 60 mg |
|---|---|
| Evaluate Efficacy of Avatrombopag in Increasing Platelet Counts in Subjects With Thrombocytopenia Scheduled for Operations | 0.75 |
Incidence of treatment emergent adverse events
No measurements were reported for this outcome.
Collected over From the time of consent through study follow up visit, up to 35 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avatrombopag 60 mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Avatrombopag 60 mg |
|---|---|
| InfluenzaInfections and infestations | 1/4 |
| Urinary Tract InfectionInfections and infestations | 1/4 |
| Urinary RetentionRenal and urinary disorders | 1/4 |
| GoutMetabolism and nutrition disorders | 1/4 |
| Subcutaneous hematomaInjury, poisoning and procedural complications | 1/4 |
| Age, Categorical(Participants) | Avatrombopag 60 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 3 |
| Age, Continuous(years) | Avatrombopag 60 mg |
|---|---|
| Mean | 66 (51 to 77) |
| Sex: Female, Male(Participants) | Avatrombopag 60 mg |
|---|---|
| Female | 2 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Avatrombopag 60 mg |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 3 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Avatrombopag 60 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Avatrombopag 60 mg |
|---|---|
| United States | 4 |
| Platelet Counts(10^9 platelets/L) | Avatrombopag 60 mg |
|---|---|
| Mean | 68 (64 to 73) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Feb 2019, 10 months.
Results were first posted in Apr 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag